financetom
Business
financetom
/
Business
/
MediWound to Begin Phase II Study of EscharEx Versus Collagenase in Venous Leg Ulcer Patients
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MediWound to Begin Phase II Study of EscharEx Versus Collagenase in Venous Leg Ulcer Patients
Oct 10, 2024 11:13 PM

11:07 AM EDT, 10/10/2024 (MT Newswires) -- MediWound ( MDWD ) said Thursday it will start a phase II clinical study in 2025 evaluating EscharEx versus a collagenase ointment that's marketed as Santyl in the US and Iruxol in Europe to treat venous leg ulcers.

The study will enroll 45 patients in the US and Europe and will run concurrently with the company's phase III trial in venous leg ulcer patients.

MediWound ( MDWD ) said the study is designed to support the biologics license application for EscharEx.

The company's shares were up nearly 1% in recent trading.

Price: 16.65, Change: +0.15, Percent Change: +0.91

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved